BR0008840B1 - derivados de camptotecina, processos para a sua preparaÇço, composiÇço farmacÊutica que os compreende e uso dos mesmos. - Google Patents

derivados de camptotecina, processos para a sua preparaÇço, composiÇço farmacÊutica que os compreende e uso dos mesmos.

Info

Publication number
BR0008840B1
BR0008840B1 BRPI0008840-4A BR0008840A BR0008840B1 BR 0008840 B1 BR0008840 B1 BR 0008840B1 BR 0008840 A BR0008840 A BR 0008840A BR 0008840 B1 BR0008840 B1 BR 0008840B1
Authority
BR
Brazil
Prior art keywords
processes
preparation
pharmaceutical composition
camptothecin derivatives
camptothecin
Prior art date
Application number
BRPI0008840-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0008840A (pt
Inventor
Sergio Penco
Lucio Merlini
Franco Zunino
Paolo Carminati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0008840A publication Critical patent/BR0008840A/pt
Publication of BR0008840B1 publication Critical patent/BR0008840B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0008840-4A 1999-03-09 2000-03-08 derivados de camptotecina, processos para a sua preparaÇço, composiÇço farmacÊutica que os compreende e uso dos mesmos. BR0008840B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99830124A EP1044977B1 (en) 1999-03-09 1999-03-09 Camptothecin derivatives having antitumor activity
PCT/EP2000/001570 WO2000053607A1 (en) 1999-03-09 2000-03-08 Camptothecin derivatives having antitumor activity

Publications (2)

Publication Number Publication Date
BR0008840A BR0008840A (pt) 2002-01-08
BR0008840B1 true BR0008840B1 (pt) 2011-12-27

Family

ID=8243303

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0008840-4A BR0008840B1 (pt) 1999-03-09 2000-03-08 derivados de camptotecina, processos para a sua preparaÇço, composiÇço farmacÊutica que os compreende e uso dos mesmos.

Country Status (38)

Country Link
US (2) US6242457B1 (enExample)
EP (1) EP1044977B1 (enExample)
JP (1) JP4610743B2 (enExample)
KR (1) KR100702085B1 (enExample)
CN (1) CN1139592C (enExample)
AR (1) AR022860A1 (enExample)
AT (1) ATE216998T1 (enExample)
AU (1) AU774174B2 (enExample)
BG (1) BG65032B1 (enExample)
BR (1) BR0008840B1 (enExample)
CA (1) CA2362760C (enExample)
CO (1) CO5180590A1 (enExample)
CZ (1) CZ304465B6 (enExample)
DE (1) DE69901379T2 (enExample)
DK (1) DK1044977T3 (enExample)
EA (1) EA003605B1 (enExample)
EE (1) EE04679B1 (enExample)
EG (1) EG23999A (enExample)
ES (1) ES2175919T3 (enExample)
HR (1) HRP20010667B1 (enExample)
HU (1) HU229506B1 (enExample)
IL (2) IL144958A0 (enExample)
IS (1) IS2003B (enExample)
ME (2) MEP4008A (enExample)
MX (1) MXPA01009081A (enExample)
NO (1) NO328363B1 (enExample)
NZ (1) NZ513393A (enExample)
PE (1) PE20001485A1 (enExample)
PL (1) PL222208B1 (enExample)
PT (1) PT1044977E (enExample)
RS (1) RS50405B (enExample)
SI (1) SI1044977T1 (enExample)
SK (1) SK287561B6 (enExample)
TN (1) TNSN00045A1 (enExample)
TR (1) TR200102603T2 (enExample)
TW (1) TWI272272B (enExample)
WO (1) WO2000053607A1 (enExample)
ZA (1) ZA200107408B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
FR2794123B1 (fr) * 1999-05-28 2001-07-27 Aventis Pharma Sa Preparation de derives de la camptothecine et de la nothapodytine
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US20040029906A1 (en) * 2001-07-31 2004-02-12 Michael Christman Inhibitors of dna polymerase sigma
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
ITRM20020305A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Camptotecine con anello lattonico modificato.
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
ITRM20030344A1 (it) * 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
WO2005092302A2 (en) * 2004-03-26 2005-10-06 Novartis Ag Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
ITRM20040242A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine.
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
CN100334089C (zh) * 2004-07-21 2007-08-29 王洋 一种9－硝基喜树碱的生产方法
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
ES2374828T3 (es) * 2004-12-15 2012-02-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinaciones de agentes terapéuticos para el tratamiento del cáncer.
ES2395930T3 (es) 2004-12-21 2013-02-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Procedimiento estereoselectivo y formas cristalinas de una camptotecina
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CA2612949C (en) 2005-07-14 2015-04-28 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
US20080213385A1 (en) * 2005-08-10 2008-09-04 Oskar Kalb Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
SI1962850T1 (sl) * 2005-12-21 2012-06-29 Sigma Tau Ind Farmaceuti Zdravljenje tumorjev, odpornih proti zdravilom
EP1989212B1 (en) * 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
EP1998809B1 (en) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
US8853233B2 (en) * 2007-02-13 2014-10-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
CA2694389C (en) * 2007-08-01 2016-01-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Treatment of pediatric tumors
EP2096113A1 (en) 2008-02-05 2009-09-02 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. 9-substituted camptothecin derivatives as antitumor compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
US10517961B2 (en) 2015-09-25 2019-12-31 ZY Therapeutics, Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
CN122497675A (zh) * 2024-06-05 2026-07-31 荣昌生物制药(烟台)股份有限公司 一种喜树碱类化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
ZA928771B (en) * 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
GB9512670D0 (en) * 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
DE69728152T2 (de) * 1996-08-19 2004-08-05 Bionumerik Pharmaceuticals, Inc., San Antonio Hoch-lipophile campothecin-derivate

Also Published As

Publication number Publication date
KR20010102519A (ko) 2001-11-15
PL355094A1 (en) 2004-03-22
PL222208B1 (pl) 2016-07-29
NO20014128L (no) 2001-08-24
EE200100466A (et) 2002-12-16
HRP20010667B1 (en) 2003-06-30
CA2362760A1 (en) 2000-09-14
ATE216998T1 (de) 2002-05-15
BR0008840A (pt) 2002-01-08
CN1343209A (zh) 2002-04-03
MEP4008A (xx) 2010-02-10
DK1044977T3 (da) 2002-07-08
JP4610743B2 (ja) 2011-01-12
IL144958A (en) 2009-08-03
HRP20010667A2 (en) 2002-08-31
NO328363B1 (no) 2010-02-01
PT1044977E (pt) 2002-09-30
HU229506B1 (en) 2014-01-28
HUP0200210A3 (en) 2004-03-29
CO5180590A1 (es) 2002-07-30
US6589939B2 (en) 2003-07-08
MXPA01009081A (es) 2002-08-30
AU3160400A (en) 2000-09-28
RS50405B (sr) 2009-12-31
JP2002539128A (ja) 2002-11-19
DE69901379T2 (de) 2002-11-07
EG23999A (en) 2008-03-19
AR022860A1 (es) 2002-09-04
US20010008939A1 (en) 2001-07-19
KR100702085B1 (ko) 2007-04-02
ES2175919T3 (es) 2002-11-16
SK11642001A3 (sk) 2002-01-07
SK287561B6 (sk) 2011-02-04
CZ304465B6 (cs) 2014-05-21
ZA200107408B (en) 2002-05-29
NZ513393A (en) 2003-04-29
EE04679B1 (et) 2006-08-15
TNSN00045A1 (fr) 2005-11-10
IS2003B (is) 2005-04-15
IS6031A (is) 2001-07-31
ME00017B (me) 2010-06-10
HK1031222A1 (en) 2001-06-08
CZ20013077A3 (cs) 2002-01-16
EP1044977B1 (en) 2002-05-02
TR200102603T2 (tr) 2002-01-21
EA003605B1 (ru) 2003-06-26
NO20014128D0 (no) 2001-08-24
PE20001485A1 (es) 2000-12-07
WO2000053607A1 (en) 2000-09-14
BG105810A (en) 2002-06-28
US6242457B1 (en) 2001-06-05
YU64301A (sh) 2005-07-19
DE69901379D1 (de) 2002-06-06
BG65032B1 (bg) 2006-12-29
CN1139592C (zh) 2004-02-25
EA200100954A1 (ru) 2002-04-25
HUP0200210A2 (hu) 2002-05-29
AU774174B2 (en) 2004-06-17
EP1044977A1 (en) 2000-10-18
TWI272272B (en) 2007-02-01
SI1044977T1 (en) 2002-08-31
CA2362760C (en) 2009-08-18
IL144958A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
BR0017030B1 (pt) derivados de tiazolilamida, processo para sua preparação, composição farmacêutica que os compreende e uso dos mesmos
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
BR9910900B1 (pt) compostos derivados de isotiazol, processo para sua preparação e composição farmacêutica dos mesmos
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
BR9909995B1 (pt) composto, processo para a preparação de um composto, formulação farmacêutica, e, uso de um composto.
BR0009083B1 (pt) derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
BR9808422B1 (pt) composto, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
BR9801606B1 (pt) composto, processo para sua preparação, substáncia farmacêutica, uso do composto e processo para a produção de uma substáncia farmacêutica.
EE200100568A (et) 6-alkenüül-, 6-alkünüül- ja 6-epoksüepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
BR9810829B1 (pt) composto heterocìclico, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica.
BR9911871B1 (pt) derivados de ácido fenoxiacético e composições farmacêuticas contendo os mesmos.
EE04151B1 (et) Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
BR9711311B1 (pt) derivado de 1,2,3,4-tetrahidroquinolina, composiÇço farmaceutica, uso de um derivado de 1,2,3,4-tetrahidroquinolina, e, processo para a preparaÇço de compostos.
BR9906373B1 (pt) compostos pirimidinona, composições farmacêuticas contendo os compostos e processos para a preparação dos mesmos.
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200100422A (et) Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
EE04311B1 (et) Asoolid, nende valmistamismeetod, kasutamine ravimina ja farmatseutiline kompositsioon
BR9807682B1 (pt) composto, uso do mesmo, composiÇço farmacÊutica, e, processos para preparar um composto.
BR9701085A (pt) Derivado de vitamina d cristalina processo para preparar o mesmo medicamento composição farmacéutica processo para preparar a mesma e uso do derivado
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
PT1118610E (pt) Novos derivados de benzeno-sulfonamida processo para a sua preparacao e as composicoes farmaceuticas que os contem

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/12/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2504 DE 02-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.